Table 3.
Baseline CSF biomarkers of PD stratified by RBD
| PD with RBD | PD without RBD | P value | |
|---|---|---|---|
| (N = 136) | (N = 214) | ||
| Aβ1–42 (pg/ml) | 354.70 ± 103.45 | 384.73 ± 90.77 | 0.005* |
| t-tau (pg/ml) | 43.76 ± 18.75 | 44.42 ± 16.89 | 0.736 |
| p-tau (pg/ml) | 14.57 ± 7.85 | 16.31 ± 11.32 | 0.121 |
| alpha-synuclein (pg/ml) | 1811.69 ± 741.35 | 1860.50 ± 818.55 | 0.578 |
| p-tau/t-tau | 0.35 ± 0.17 | 0.39 ± 0.25 | 0.130 |
| t-tau/Aβ1–42 | 0.13 ± 0.07 | 0.12 ± 0.05 | 0.056 |
Results are mean ± (SD). P value was assessed using two-tailed Student t test for each variable. *P value statistically significant. The PD with RBD patients had significantly lower contents of CSF Aβ1–42
Abbreviations: PD Parkinsonr’s disease, RBD Rapid eye movement sleep behavioral disorder, CSF cerebrospinal fluid, t-tau total tau, p-tau phosphorylated-tau, Aβ β-amyloid